| Identification | Back Directory | [Name]
SARALASIN | [CAS]
34273-10-4 | [Synonyms]
SARALASIN
SARALASIN USP/EP/BP
M.W. 912.05 C42H65N13O10
(SAR1,VAL5,ALA8)-ANGIOTENSIN II
SAR-ARG-VAL-TYR-VAL-HIS-PRO-ALA
SAR-ARG-VAL-TYR-VAL-HIS-PRO-ALA-OH
[SAR1,VAL5, ALA8]ANGIOTENSIN II, HUMAN
[Sar1,Val5,Ala8]angiotensin II【rabbit】
(Sar1,Val5,Ala8)-Angiotensin II
Saralasin
Saralasin/[Sar1,Val5, Ala8] Angiotensin II
SAR-ARG-VAL-TYR-VAL-HIS-PRO-ALA: SAR-RVYVHPA
Sar-L-Arg-L-Val-L-Tyr-L-Val-L-His-L-Pro-L-Ala-OH
[sar1, val5, ala8]-angiotensin ii acetate hydrate
[Sar1, Val5, Ala8]-AngiotensinII hydrate acetate salt
[Sar1, Val5, Ala8]-Angiotensin II acetate salt hydrate
L-Alanine, N-methylglycyl-L-arginyl-L-valyl-L-tyrosyl-L-valyl-L-histidyl-L-prolyl- | [Molecular Formula]
C42H65N13O10 | [MDL Number]
MFCD00167510 | [MOL File]
34273-10-4.mol | [Molecular Weight]
912.05 |
| Hazard Information | Back Directory | [Uses]
Antihypertensive. | [Definition]
ChEBI:Saralasin is an oligopeptide. | [Brand name]
Sarenin (Procter & Gamble). | [in vivo]
Saralasin (intravenous injection, 5-50 μg/kg, a single dose) ameliorates the oxidative stress and tissue injury in cerulein-induced pancreatitis[5].
Saralasin (subcutaneous injection, 10 and 30 mg/kg, a single dose) increases serum renin activity (SRA) in normal, conscious rats, without markedly altering blood pressure or heart rate[6]. | Animal Model: | Cerulein-induced acute pancreatitis rats model[5] | | Dosage: | 5, 10, 20, and 50 μg/kg, a single dose. | | Administration: | Intravenous injection | | Result: | Restored the pancreatic morphological characteristics to the control level.
Reduced pancreatic injury and suppressed the glutathione depletion induced by cerulean.
|
| Animal Model: | Male Sprague-Dawley rats[6] | | Dosage: | 10 and 30 mg/kg, a single dose. | | Administration: | Subcutaneous injection | | Result: | Stimulated renin release without altering blood pressure or heart rate at the time of measuring serum renin levels 20 minutes after injection. |
|
|
|